297 related articles for article (PubMed ID: 19261853)
1. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.
Liu Z; Meray RK; Grammatopoulos TN; Fredenburg RA; Cookson MR; Liu Y; Logan T; Lansbury PT
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4635-40. PubMed ID: 19261853
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a key role in protein stability, but its farnesylation is not required for membrane association in primary neurons.
Bishop P; Rubin P; Thomson AR; Rocca D; Henley JM
J Biol Chem; 2014 Dec; 289(52):36140-9. PubMed ID: 25326379
[TBL] [Abstract][Full Text] [Related]
3. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
4. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy.
Kabuta T; Furuta A; Aoki S; Furuta K; Wada K
J Biol Chem; 2008 Aug; 283(35):23731-8. PubMed ID: 18550537
[TBL] [Abstract][Full Text] [Related]
5. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
6. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy.
Cartier AE; Ubhi K; Spencer B; Vazquez-Roque RA; Kosberg KA; Fourgeaud L; Kanayson P; Patrick C; Rockenstein E; Patrick GN; Masliah E
PLoS One; 2012; 7(4):e34713. PubMed ID: 22514658
[TBL] [Abstract][Full Text] [Related]
8. Pathological proteins in Parkinson's disease: focus on the proteasome.
Snyder H; Wolozin B
J Mol Neurosci; 2004; 24(3):425-42. PubMed ID: 15655264
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1.
Konya C; Hatanaka Y; Fujiwara Y; Uchida K; Nagai Y; Wada K; Kabuta T
Neurochem Int; 2011 Aug; 59(2):251-8. PubMed ID: 21693148
[TBL] [Abstract][Full Text] [Related]
10. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
11. Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy.
Kabuta T; Wada K
Autophagy; 2008 Aug; 4(6):827-9. PubMed ID: 18635949
[TBL] [Abstract][Full Text] [Related]
12. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.
Liu Y; Fallon L; Lashuel HA; Liu Z; Lansbury PT
Cell; 2002 Oct; 111(2):209-18. PubMed ID: 12408865
[TBL] [Abstract][Full Text] [Related]
13. The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells.
Kyratzi E; Pavlaki M; Stefanis L
Hum Mol Genet; 2008 Jul; 17(14):2160-71. PubMed ID: 18411255
[TBL] [Abstract][Full Text] [Related]
14. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1.
Meray RK; Lansbury PT
J Biol Chem; 2007 Apr; 282(14):10567-75. PubMed ID: 17259170
[TBL] [Abstract][Full Text] [Related]
15. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.
Kabuta T; Setsuie R; Mitsui T; Kinugawa A; Sakurai M; Aoki S; Uchida K; Wada K
Hum Mol Genet; 2008 May; 17(10):1482-96. PubMed ID: 18250096
[TBL] [Abstract][Full Text] [Related]
16. N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.
Kim HJ; Kim HJ; Jeong JE; Baek JY; Jeong J; Kim S; Kim YM; Kim Y; Nam JH; Huh SH; Seo J; Jin BK; Lee KJ
PLoS One; 2014; 9(6):e99654. PubMed ID: 24959670
[TBL] [Abstract][Full Text] [Related]
17. Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1.
Shimshek DR; Schweizer T; Schmid P; van der Putten PH
Sci Rep; 2012; 2():262. PubMed ID: 22355774
[TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor.
Tan YY; Zhou HY; Wang ZQ; Chen SD
Mol Cell Biochem; 2008 Nov; 318(1-2):109-15. PubMed ID: 18622688
[TBL] [Abstract][Full Text] [Related]
19. Localization of ubiquitin C-terminal hydrolase L1 in mouse ova and its function in the plasma membrane to block polyspermy.
Sekiguchi S; Kwon J; Yoshida E; Hamasaki H; Ichinose S; Hideshima M; Kuraoka M; Takahashi A; Ishii Y; Kyuwa S; Wada K; Yoshikawa Y
Am J Pathol; 2006 Nov; 169(5):1722-9. PubMed ID: 17071595
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.
Osaka H; Wang YL; Takada K; Takizawa S; Setsuie R; Li H; Sato Y; Nishikawa K; Sun YJ; Sakurai M; Harada T; Hara Y; Kimura I; Chiba S; Namikawa K; Kiyama H; Noda M; Aoki S; Wada K
Hum Mol Genet; 2003 Aug; 12(16):1945-58. PubMed ID: 12913066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
